| Incyte in Neutral Lane |
Zacks.comWe are also encouraged by Incyte's collaborations with established players like Novartis (NVS) and Eli Lilly (LLY). We believe the association of big pharmaceutical companies will bolster the company with much needed financial strength and experience.
|
| It Pays to Be CEO of Salisbury-Based Jubilant Cadista Pharmaceuticals |
Citybizlist (press release)Before joining Cadista, Delaney spent over 20 years in the pharmaceutical industry, working for companies such as Eli Lilly and Company, Johnson and Johnson (Ortho Biotech), HEB Grocery Company and Teva Pharmaceuticals. Most recently, he held the ...
|
| U.S. Patents Awarded to Inventors in Indiana (Feb. 10) |
Targeted News Service (subscription)9 -- Eli Lilly, Indianapolis, has been assigned a patent (8110580) developed by Zhaogen Chen, Indianapolis, Shaojuan Jia, Zionsville, Ind., and James Lee Toth, Knightstown, Ind., for a thiophene pyrazolopyrimidine compounds. The abstract of the patent ...
|
| Glaxo Executive: Sales-Force Changes Have Helped Promoted-Product Sales |
Fox Business(MRK) and Eli Lilly & Co. (LLY) have also downsized and re-evaluated how they pitch drugs to doctors in light of declining sales for blockbuster drugs, and the high costs of keeping large sales forces. At the same time, UK-based Glaxo has softened its ...
|
| 10 Ex-Dividend Stocks With Buy Ratings |
TheStreet.comBy Alexandra Zendrian 02/10/12 - 08:01 AM EST NEW YORK (TheStreet) -- The following stocks go ex-dividend Monday, meaning an investor must purchase the shares Friday to qualify for the next dividend payment: DuPont(DD), Target(TGT), Eli Lilly(LLY), ...
|
| Massive Government Funding puts Anavex in Ideal Situation (AVXL, SBUX, RL) |
SmallCap NetworkOther efforts by major pharmaceutical companies such as Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) areare dedicated to removing amyloid-beta plaque. The Analex Life-Science approach, detailed in previous articles on www.smallcapnetwork.com, ...
|
| The Truly Staggering Cost Of Inventing New Drugs |
ForbesDuring the Super Bowl, a representative of the pharmaceutical company Eli Lilly posted the on the company's corporate blog that the average cost of bringing a new drug to market is $1.3 billion, a price that would buy 371 Super Bowl ads, ...
|
